Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease (PAD), according to results of the MOBILITY trial presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.
Resverlogix Corp. is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule.
A new balloon catheter system could advance the endovascular approach to treating obstructed arteries in the leg, offering an alternative to surgical revascularization. Peripheral artery disease affects about 12 to 14 percent of the general population, and revascularization can be achieved through bypass surgery or a number of minimally invasive endovascular techniques that seek to reduce or eliminate symptoms of reduced blood flow by improving tissue perfusion.
Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.
Angioslide Ltd. a provider of Embolic Capture Angioplasty solutions, today announced that it has received FDA 510(K) clearance for its new 3X100mm PROTEUS device for treating Peripheral Artery Disease in below the knee (BTK) vasculature.
Depression may be associated with an increased risk of arterial narrowing in the legs and pelvis, a condition known as peripheral artery disease (PAD), according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions in Chicago.
Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb ischemia caused by peripheral artery disease (PAD), a complication of diabetes.
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
Intact Vascular, a medical device company and developer of products for minimally invasive peripheral vascular procedures, today announced its European notified body has granted the company ISO Certification and CE Mark approval for Tack-it Endovascular Stapler device.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has been awarded a Phase I NIH-STTR grant from the National Institute of Neurological Disorders and Stroke (NINDS) for the further development of its Thin-Film Nitinol (TFN)-covered stent for the potential treatment of brain aneurysms.
Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the fourth quarter and full year ended December 31, 2011.
A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.
Vascular Magnetics, the first start-up company spun off by The Children's Hospital of Philadelphia, has raised $7 million to advance development of an innovative drug delivery system using magnetically targeted nanoparticles to treat peripheral artery disease.
If you could find out if you had an increased risk of heart attack or stroke, wouldn't you want to know? Even if you are fit and healthy, coronary artery disease (CAD) or peripheral artery disease (PAD) are conditions with little to no symptoms and can put you at an increased risk of heart attack or stroke.
A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones.
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
Boston Scientific Corporation reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow.
Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication.
AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.
Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.